DI NUNNO, VINCENZO
 Distribuzione geografica
Continente #
NA - Nord America 1.744
EU - Europa 917
AS - Asia 663
AF - Africa 90
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 2
Totale 3.421
Nazione #
US - Stati Uniti d'America 1.737
SG - Singapore 241
CN - Cina 195
SE - Svezia 177
GB - Regno Unito 170
IT - Italia 147
VN - Vietnam 132
DE - Germania 110
IE - Irlanda 71
RU - Federazione Russa 70
CH - Svizzera 55
CI - Costa d'Avorio 45
IN - India 41
TG - Togo 28
FI - Finlandia 26
FR - Francia 22
BG - Bulgaria 17
JP - Giappone 16
BE - Belgio 14
ID - Indonesia 12
ZA - Sudafrica 12
EE - Estonia 11
JO - Giordania 9
UA - Ucraina 7
AT - Austria 6
NL - Olanda 6
SK - Slovacchia (Repubblica Slovacca) 5
HK - Hong Kong 4
NG - Nigeria 4
AU - Australia 3
BD - Bangladesh 3
MX - Messico 3
TR - Turchia 3
CA - Canada 2
MY - Malesia 2
NI - Nicaragua 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
BR - Brasile 1
EU - Europa 1
LB - Libano 1
MA - Marocco 1
NO - Norvegia 1
PL - Polonia 1
RO - Romania 1
SA - Arabia Saudita 1
UZ - Uzbekistan 1
Totale 3.421
Città #
Chandler 239
Singapore 212
Santa Clara 161
Fairfield 150
Southend 144
Ashburn 107
Seattle 79
Princeton 72
Dublin 71
Houston 70
Woodbridge 67
Dong Ket 65
Boardman 61
Wilmington 59
Bern 55
Cambridge 52
Ann Arbor 49
Abidjan 45
Bologna 32
Lomé 28
Helsinki 26
Berlin 25
Beijing 20
Sofia 17
Westminster 15
Brussels 12
Jakarta 12
Redwood City 12
Turin 12
Milan 11
Nanjing 10
New York 10
Amman 9
Des Moines 9
Olalla 9
Redmond 9
Falls Church 8
San Diego 8
Yubileyny 8
Boydton 7
Shanghai 7
Florence 6
Glasgow 6
London 6
Naples 6
Shenyang 6
Tianjin 6
Bühl 5
Forlì 5
Guangzhou 5
Harbin 5
Jinan 5
Kyoto 5
Montescudo 5
Wuhan 5
Zhengzhou 5
Žilina 5
Abeokuta 4
Bentivoglio 4
Changsha 4
Changzhou 4
Chicago 4
Hebei 4
Kumar 4
Los Angeles 4
Ningbo 4
Phoenix 4
Qingdao 4
Shijiazhuang 4
Torino 4
Baoding 3
Cardiff 3
Hangzhou 3
Kuban 3
Kunming 3
New Haven 3
Pescara 3
Rome 3
Sacramento 3
Shenzhen 3
Vienna 3
Xi'an 3
Aspremont 2
Boston 2
Bremen 2
Canberra 2
Casalgrande 2
Catania 2
Central 2
Chongqing 2
Clearwater 2
Costa Mesa 2
Dearborn 2
Frankfurt Am Main 2
Fuzhou 2
Groningen 2
Haikou 2
Isera 2
Istanbul 2
Kilburn 2
Totale 2.284
Nome #
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 179
Circulating tumor cells in genitourinary tumors 158
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 146
Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients 135
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 126
Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors 124
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 117
Immune checkpoint inhibitors for metastatic bladder cancer 116
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 112
The human microbiota and prostate cancer: Friend or foe? 100
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 99
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. 97
Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis. 88
Immortal time bias question in the association between toxicity and outcome of immune checkpoint inhibitors 86
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. 83
Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem 79
Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study 76
The clinical and prognostic role of ALK in glioblastoma 75
Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.09.008 72
Glioblastoma: Emerging treatments and novel trial designs 71
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 70
Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases 67
Diagnostic and Therapeutic Strategy in Anaplastic (Malignant) Meningioma, CNS WHO Grade 3 66
Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer? 64
Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review 62
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 62
Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study 61
Idh1 non-canonical mutations and survival in patients with glioma 59
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients 58
Rare Primary Central Nervous System Tumors in Adults: An Overview 57
IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas 57
Discovering the molecular landscape of meningioma: The struggle to find new therapeutic targets 57
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: An unassessed issue 54
IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment 49
Machine learning in neuro-oncology: toward novel development fields 47
Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light 45
Meningioma: Not always a benign tumor. A review of advances in the treatment of meningiomas 44
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 36
The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target? 34
Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. 34
Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients? 33
Cabazitaxel in metastatic prostate cancer 32
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 23
The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma 22
null 22
Molecular mechanisms related to hormone inhibition resistance in prostate cancer 21
Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors 21
Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back? 20
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 20
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer 19
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 16
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 15
Optimizing renal function and outcome of patients with cT2 renal cell carcinoma 14
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue 11
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 9
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 8
N-Myc a key gene promoting a worst prostate cancer progression 8
Future perspectives for personalized immunotherapy in renal cell carcinoma 7
Pembrolizumab plus axitinib: A new treatment option for patients with metastatic renal cell carcinoma 6
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes 6
Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462–8 6
Targeting Mitochondria in Glioma: New Hopes for a Cure 3
Totale 3.564
Categoria #
all - tutte 13.425
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.425


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020229 0 0 0 0 0 0 0 69 68 43 29 20
2020/2021338 46 12 29 3 21 4 6 6 35 14 7 155
2021/2022609 12 18 15 24 53 22 9 61 56 59 187 93
2022/2023974 90 106 42 100 64 120 28 67 181 37 52 87
2023/2024309 44 62 25 34 19 45 17 26 8 18 2 9
2024/2025789 65 165 108 86 236 62 64 3 0 0 0 0
Totale 3.564